AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

As reported by cnbc.com

AstraZeneca on Tuesday released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease, boosting ...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on cnbc.com ↗

Market Samachar is a news aggregator. This article was originally published by cnbc.com. Tap the button above to read the full story on their site.

INDIAN India's leading high frequency trading firm turns to bonds for capital Markets-Economic Times
INDIAN US stocks today: US stocks mixed at open as Gulf tensions send oil to over six-week high Markets-Economic Times
INDIAN Japanese investors favoured foreign equities over bonds in August Markets-Economic Times
INDIAN India bonds inch up as traders assess RBI liquidity steps Markets-Economic Times
INDIAN Thailand's Kasikornbank launches $800 million US dollar bond sale, term sheet shows Markets-Economic Times
INDIAN Amazon hires banks for first ever sterling bond sale Markets-Economic Times
COMPANIES Bajaj Finance acquires 5% stake in TrueFan AI as part of Finserv Intelligence Stocks-Markets-Economic Times
INDIAN 1200% rally in five years! Small cap multibagger stock under ₹20 to be in focus on Wednesday; here's why mint - markets

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

More from Market Samachar